Hypertension News

Patients with chronic kidney disease who were initiated on renin-angiotensin system inhibitors experienced greater benefits, including a reduced need for dialysis, than those initiated on calcium channel blockers.

A study of living kidney donors in Denmark found that while donation was associated with a greater risk for hypertension, it did not appear to increase the likelihood of donors developing cardiovascular disease.

For patients with both heart and kidney failure, beta-blocker use was associated with decreased mortality rates within 1 year after dialysis initiation.

Use of alpha-blockers – commonly prescribed to treat hypertension – was associated with eGFR decline in patients with chronic kidney disease, leading to an increased need for dialysis or transplantation.

The most prevalent comorbidity in patients hospitalized for COVID-19 was hypertension, which was also a risk factor for acute kidney injury in the ED and mortality in these patients, researchers found in two separate studies.

Results from a pilot trial showed taking at-home blood pressure measurements was feasible for patients receiving in-center hemodialysis, with high demonstrated adherence rates.

A study conducted in France found adverse drug reactions were common in patients with chronic kidney disease, most notably due antithrombotic agents, but researchers suggested many of these reactions may be preventable.

In a study of patients with hypertension, declining kidney function was associated with risk for incident dementia and cognitive impairment.

Pre-donation hypertension was associated with a higher risk of uncontrolled post-donation systolic blood pressure among older kidney donors, according to findings presented at the American Transplant Congress.

Patients with chronic kidney disease and hypertension who underwent intensive blood pressure lowering had increases in fibroblast growth factor 23 levels regardless of changes in eGFR, according to a published study.